The global digital therapeutics market, a key player in brain health, is predicted to surge from USD 11.98 billion in 2026 to approximately USD 65.31 billion by 2035, reports Precedence Research. Explosive growth reflects a widespread public desire for solutions to maintain cognitive function and prevent dementia. Yet, while the market booms, many truly promising scientific breakthroughs remain years from clinical application. The tension between immediate commercial offerings and long-term scientific validation means companies are aggressively capitalizing on public anxiety and hope. The result will likely be a proliferation of both innovative and unproven solutions, making informed consumer choices more critical than ever.
The Exploding Market for Cognitive Wellness
The global cognitive assessment and brain health market hit USD 9.40 billion in 2025, while the digital therapeutics market reached USD 9.73 billion in the same year, both according to Precedence Research. The fact that digital therapeutics, a component of brain health, appears larger than the entire cognitive assessment market suggests a significant definitional overlap or miscategorization in reporting. Regardless, the figures confirm a burgeoning industry, driven by accelerating commercial interest in cognitive wellness and prevention.
Key Segments Driving Growth
In 2025, brain health supplements dominated the market with a 58% share, while central nervous system (CNS) / neuroscience digital therapeutics captured 32.60% of its segment. Both figures are from Precedence Research. Technology and supplements, rather than pharmaceutical breakthroughs, are currently the primary commercial vehicles for addressing brain health concerns.
Scientific Progress Fuels Prevention Hopes
The Dominantly Inherited Alzheimer Network (DIAN) is designing primary prevention trials, enrolling mutation carriers with near-certain risk of early-onset dementia, reports Nature. The DIAN-TU Primary Prevention Platform trial also uses biomarker outcomes to detect and quantify effects of preventing Aβ accumulation. Scientific efforts underpin the market's expansion, offering long-term hope for neurodegenerative disease prevention. Yet, the immediate commercial boom in digital therapeutics reveals an industry prioritizing rapid monetization over the slow, rigorous path of scientific validation.
Regional Dominance and Emerging Markets
North America consistently leads both the cognitive assessment and brain health market (40% in 2025) and the digital therapeutics market (43.91% in 2025), according to Precedence Research. While North America remains dominant, the Asia-Pacific region is projected for the fastest growth. A global shift in future market influence is signaled.
The Horizon of Future Therapies
Breakthroughs in RNA therapy hint at a future where targeted biological interventions could definitively prevent or reverse neurodegenerative processes. For instance, short RNA molecules stopped or reversed abnormal clumping of the TDP-43 protein in cell and animal models, reports the National Institutes of Health. Early-stage advancements offer a glimpse into truly transformative treatments. Yet, the market's current trajectory, heavily reliant on consumer-facing products with limited scientific backing (like the 58% share of supplements in 2025), sets the stage for regulatory bodies to play catch-up, potentially leaving consumers vulnerable to ineffective or misleading brain health claims.
The digital therapeutics market's projected 20.97% CAGR through 2035, despite the 2023 bankruptcy of a prominent player like Pear Therapeutics, suggests that while commercialization will continue aggressively, robust validation will likely become a critical differentiator for sustained success.
